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Endovascular treatment of
genetically linked aortic diseases
Introduction
Over the past 10 years endovascular
treatment has become the method of
ﬁrst choice for both infrarenal aortic
aneurysms (AAA) and thoracic aortic
disease, e.g. aneurysms, Stanford B dis-
section, intramural hematoma (IMH),
penetrating aortic ulcer (PAU) and
traumatic rupture. This is supported
by numerous randomized studies (e.g.
EVAR1, DREAM OVER, INSTEAD and
ADSORB) [1–7], as well as large inter-
national registry studies (ENGAGE and
GREAT) [8, 9]. Endovascular repair
has also become established as the ﬁrst-
line approach in the emergency setting
of ruptured AAA in many centers with
the relevant practical experience [10].
Here again, results from randomized stu-
dies (IMPROVE, AJAX, ECAR) are now
available and provide valuable data on
establishing the indications and choos-
ing the method [11–14]. Establishing
the indications for endovascular aor-
tic repair (EVAR) in AAA is guided
by conventional aneurysm surgery and
allows treatment from an aneurysm
diameter of 5 cm. As is well known,
aneurysm morphology, comorbidities,
patient treatment wishes and operator or
center-speciﬁc perioperative mortality
and morbidity rates inﬂuence the choice
of treatment. In contrast, establishing
the indications for thoracic endovascular
aortic repair (TEVAR) in the heteroge-
neous group of thoracic aortic diseases
depends on the diameter in the case of
asymptomatic thoracic aortic aneurysm
The German version of this article can be found
underdoi: 10.1007/s00772-016-0192-0.
(TAA) and PAU and, in the case of
complex type B dissections or IMH, on
symptoms, the presence of organ com-
plications or imaging predictors of rapid
progression [15].
Technical and clinical success is based
inthe longandtheshort termonadequate
and “healthy” landing zones, both proxi-
mal and distal to the aortic pathology, for
the planned endograft. Higher reinter-
vention rates and increasedmortality are
known and have been described follow-
ing EVAR in which the instructions for
use (IFU) were not fully observed [16].
» Technical and clinical success
depends on adequate landing
zones
Age and gender also impact treatment
outcomes. For example, females with
aortic dissection exhibit a higher com-
plication rate in the spontaneous course
Table 1 Subtypes of Ehlers-Danlos syndrome
Nomenclature Type Clinical symptoms Mode of inheritance
Classical I, II Rarely vascular complications AD
Hypermobility III Arthritis AR
Vascular IV Rupture of arteries, uterus,
intestines, skin
AD
Kyphoscoliosis VI A, VI B Hypotonia, osteoporosis,
kyphoscoliosis, rupture of
arteries or ocular globe
AR
Arthrochalasia VII A, VII B Hip subluxation, osteoporosis AD
Dermatosparaxis VII C Doughy, loose skin AR
Other V Loose, hyperelastic skin X-chromosomal
VIII Periodontitis AD
IX Loose skin, osteoporosis X-chromosomal
X Petechiae ?
AD autosomal dominant, AR autosomal recessive
as well as postoperatively. The Cleveland
working group led by Ourielund and
Greenberg was able to show the eﬀect
of gender on the outcome of EVAR in
their own patient population (n = 704,
606 males, 86.1%) [17]. Although fe-
maleshadsomewhatsmallerAAA(5.2vs.
5.4 cm), both groups were comparable in
terms of age and comorbidities. No gen-
der-speciﬁc diﬀerences were observed
in terms of 30-day mortality or in the
mean follow-up in terms of migration,
reintervention or conversion rate. Other
overview articles, however, reported
higher long-term mortality rates among
females with AAA 5 years following
EVAR [18]. Against this backdrop, ge-
netic aortic diseases, such as Marfan or
Ehlers-Danlos syndromes, play a par-
ticularly prominent role. These patient
groups are young, experience syndrome-
speciﬁc multimorbidity and the aortic
disease shows greater progressive dilata-
tion. The aim of this overview article
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Ince et al. [16] 6 ns 5 (83) 0 0 0 0
Nordon et al. [17] 7 3 (42.8) 7 (100) 1 (14) 0 0 ns
Geisbüsch et al. [18] 6 ns 3 (50) 0 0 0 Type I: 1 (16.6)
Botta et al. [19] 12 5 (41.7) 12 (100) 0 0 0 Type I: 1 (8.3)
Type II: 2 (16.7)
Marcheix et al. [20] 15 2 (13.3) 11 (73) 0 0 1 (6.7) Type I: 4 (26.7)
Type II: 1 (6.7)
Waterman et al. [21] 16 3 (18.7) 15 (94) 1 (6.2) ns ns Type I: 3 (18.7)
Type II: 1 (6.2)
Eid-Lidt et al. [22] 10 10 (100) 5 (50) 1 (10) 0 1 (10) ns
ns not specified, TIA transient ischemic attack













Ince et al. [16] 6 51 (12–74) ns 0 2 1
Nordon et al. [17] 6 16 (3–54) Type I: 1 (16.7) 2 0 1
Type III: 1 (16.7)
Geisbüsch et al. [18] 6 32.8 (3–79) Type I: 1 (12.5) 1 0 1
Type III 1 (12.5)
Botta et al. [19] 12 31 (3–57) Type I: 1 (8.3) 1 1 0
Type III: 1 (12.5)
Marcheix et al. [20] 15 25 (10–59) Type I: 4 (26.7) 3 5 3
Type III: 1 (6.7)
Waterman et al. [21] 15 9 (0–46) ns 4 7 3
Eid-Lidt et al. [22] 9 59.6 (9–102) Type I: 1 (22.2) 3 0 1
Type II: 1 (22.2)
Total 69 32 13 14 15 10
ns not specified
is to brieﬂy discuss the most important
aortic diseases through the prism of
endovascular treatment options and the
importance.
Genetic aortic diseases
The following provides a short overview
of the fourbest-knowndiseasesordisease
complexesinvolvingimpairedvascularor
aortic wall integrity due to genetic con-
nective tissue defects. As such, they are
referred to as connective tissue diseases
(CTD).Thedescriptionofdiseases in this
article makes no claim to be exhaustive
and the reader is referred to further lit-
erature [19–21].
Marfan’s syndrome (MS)
With a prevalence of 1 in 10,000 in-
dividuals Marfan’s syndrome, an auto-
somal dominant disorder ﬁrst clinically
described in 1896 by Antonin-Bernard
Marfan and genetically conﬁrmed in the
early 1990s, is caused by a mutation of
the ﬁbrillin-1 gene (FBN1), which maps
to chromosome 5q21.1. The Ghent cri-
teria, as well as complementary genetic
tests that have become limited in their
practicability due to the now >600 dif-
ferent mutations, are used for the typing
and conﬁrmation of Marfan’s syndrome
[21]. In addition to the eyes and muscu-
loskeletal system, large lumenarteries are
particularly aﬀected. Involvement of the
cardiac valve and aortic root aswell as the
risk of aortic dissection and rupture asso-
ciated with dilatation, crucially aﬀect the
prognosis. Dilatation of the sinus of Val-
salva already begins in intrauterine life
during the embryonic period. There are
no absolute diameters on which to base
the indications for surgery in children
and adolescents. Growth of >1 cm/year
or severe valve insuﬃciency and aZ score
(statistical value with respect to mean
value and standard deviation in aortic
root diameter) >2–3 provide orientation.
Surgery is recommended in adults with
an aortic root diameter of 50mm and
above [21]. Isolated infrarenal aortic in-
volvement is not known. Thanks to early
identiﬁcation and treatment, the mean
S2 Gefässchirurgie · Suppl 1 · 2017
life expectancy of patients with Marfan’s
syndrome can now be increased to as
much as 60 years [22].
Vascular type (type IV) Ehlers-
Danlos syndrome (EDS)
Ehlers-Danlos syndrome (EDS) is a he-
terogeneous, genetically linked and gen-
erally autosomal dominant disorder of
collagen synthesis for which 10 sub-
types have been identiﬁed (. Table 1).
The most common subtypes are classical
types I and II, which are rarely associated
with vascular complications. Vascular
type IV, caused by defective type III pro-
collagen, is relevant in vascular surgery
(prevalence 1:100,000–1:250,000). The
defect, encoded by the COL3A1 gene,
results in extreme vascular fragility. De-
tailed genetic anddiagnostic information
can be found in works by Superti-Furga
et al. [23] and Beighton et al. [24]. Due
to vascular rupture, the most common
cause of death, the life expectancy of
aﬀected individuals is markedly cur-
tailed at 48 years on average. Vascular
rupture, which more commonly aﬀects
medium-sized arteries, in contrast to
Marfan’s syndrome, can occur irrespec-
tive of diameter. Pepin et al. published
a series of 220 type IV EDS patients, 89%
of which experienced complications at
the age of 40 years. Mortality was 60%
(60% aortic rupture; 15% organ rupture,
in particular heart, uterus, spleen, and
liver; 7% intracranial hemorrhage; 12%
hemorrhage of unknown etiology). True
aneurysms are rare in EDS IV [25, 26].
Loeys-Dietz syndrome (LDS)
Loeys-Dietz syndrome (LDS) is an aor-
tic syndrome characterized by aortic
aneurysm formation associated with
marked vascular tortuosity, craniofa-
cial abnormalities and biﬁd uvula. It
is caused by heterozygous mutations
in the genes encoding transforming
growth factor beta (TGFbeta) recep-
tors I and II [27]. The LDS is clinically
distinct from Marfan’s syndrome in that
the aortic root may rupture and dis-
sect in early childhood and at a small
diameter. Establishing a family history
and screening are crucial. As with EDS,
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Endovascular treatment of genetically linked aortic diseases
Abstract
Background. The most important structural
proteins of the vascular wall are collagen and
elastin. Genetically linked connective tissue
diseases lead to degeneration, aneurysm
formation and spontaneous dissection or
rupture of arteries. The most well-known are
Marfan syndrome, vascular Ehlers-Danlos
syndrome (type IV), Loeys-Dietz syndrome
and familial aortic aneurysms and dissections.
Objective. This review article addresses the
current status of endovascular treatment
options for important connective tissue
diseases.
Material and methods. Evaluation of
currently available randomized studies and
registry data.
Results. The treatment of choice for patients
that are mostly aﬀected at a young age is
primarily conservative or open repair. There is
only limited evidence for endovascular aortic
repair (EVAR) of abdominal aneurysms or
thoracic endovascular aortic repair (TEVAR).
Conclusion. The progression of the disease
with dilatation leads to secondary endoleaks
and high reintervention rates with uncertain
long-term results. For this reason, there is
currently consensus that EVAR and TEVAR
should be limited to justiﬁed exceptional
cases and emergency situations in patients
with genetically linked aortic diseases.
Keywords
Connective tissue disease · Marfan · Aorta ·
Endovascular aortic repair · Thoracic
endovascular aortic repair
Endovaskuläre Therapie genetisch bedingter
Aortenerkrankungen
Zusammenfassung
Hintergrund. Die wichtigsten Struktur-
proteine der Gefäßwand sind Kollagen
und Elastin. Genetisch bedingte Bindege-
webserkrankungen führen zu Degeneration
und Aneurysmabildung, spontanen
Dissektionen oder Rupturen von Arterien.
Am bekanntesten sind das Marfan-Syndrom,
das Ehlers-Danlos-Syndrom vom vaskulären
Typ, das Loeys-Dietz-Syndrom sowie familiäre
Aortenaneurysmen und Dissektionen.
Fragestellung.Welchen Stellenwert haben
endovaskuläre Behandlungsoptionen in der
Therapie aortaler Pathologien auf dem Boden
von Bindegewebserkrankungen?
Material und Methoden. Auswertung
aktueller randomisierter Untersuchungen
und Registerstudien.
Ergebnis. Die Therapie der Wahl der meist
bereits in jungem Alter betroﬀenen Patienten
ist primär konservativ bzw. oﬀen chirurgisch.
Zur endovaskulären Therapie abdomineller
Aneurysmen (EVAR) oder thorakalen
Aortenpathologien (TEVAR) gibt es nur wenig
Evidenz.
Schlussfolgerungen. Die Progression der
genetisch bedingten Grunderkrankung
mit konsekutiver Aortendilatation führt zu
sekundären Endoleckagen und vermehrten
Reinterventionenmit unsicherem Langzeit-
ergebnis. Deshalb besteht derzeit Konsensus,
dass EVAR und TEVAR bei genetisch beding-




Bindegewebserkrankung · Marfan · Aorta ·
EVAR · TEVAR
mean life expectancy is approximately
22–37 years. Histologically, collagen and
elastin abnormalities, triggered by the
TGFbeta signaling pathway, are present.
For more details, readers are referred to
the original works by the author that
ﬁrst described the disorder, Prof. Bart
Loeys [28]. Aneurysmal widening of
the aorta aﬀects only approximately 9%
of LDS patients. A rapid growth rate
of 1.8mm/year in the case of a thoracic
localization is worthy of note. Although
the infrarenal aorta is less susceptible
to aneurysmal lesions, it is generally
elongated by a factor of two [29].
In addition to the administration of
beta-blockers and possibly also losartan,
current recommendations include con-
ventional surgical treatment. The indica-
tions for prophylactic surgery need to be
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Fig. 18 Highly comorbid female patientwith suspected type IV Ehlers-Danlos syndrome and60-mm
asymptomatic juxtarenal abdominal aortic aneurysm thatwas declined for a fenestrated endograft
and, due tomorphology, untreatable using a chimney technique.Preoperative computed tomogra-
phy angiography (CTA) shows the origin of themore proximal left renal artery at the level of the su-
periormesenteric artery (a), the juxtarenal start of the aneurysm (b) and themaximum transverse
diameter (c). Intraoperative digital subtraction angiography (DSA) before and after implantation of
aNellixgraftshowinganeurysmocclusionandnoindicationofanendoleak(d, e). PostoperativeCTAat
6weeksshowsa regularlyperfusedendograftandno indicationofmigrationor type Iaendoleak;how-
ever, there is evidence of a type II endoleak in the region of the right distal Nellix limb.Emergency CTA
approximately 6months following implantation showsa secondary-type Ia endoleak (g) aswell as the
dorsally contained rupturewith contrastmediumextravasation and retroperitoneal hematoma (h).
Images kindly provided by the Department of Diagnostic and Interventional Radiology, Heidelberg
University Hospital
made on an individual basis, taking risks
and beneﬁts into consideration. On av-
erage, vascular repair is necessary at the
average age of 16.9 years [22]. In adults,
the indication to treat the thoracoabdom-
inal and infrarenal aorta is established at
4.0 cm [21]. Multiple interventions and
reinterventions are common in EDS.
Familial thoracic aortic aneurysms
and dissections (FTAAD)
A familial predisposition to thoracic aor-
tic aneurysms and dissections (FTAAD)
is seen in 11–19% of cases. So far
ﬁve gene loci on three diﬀerent genes
have been mapped (TAAD1: 5q13–14,
FAA1: 11q23–24, TAAD2: 3p24–25 and
MYH11: 16p12.2–13.13). Furthermore,
alpha-actin mutations (ACTA2) are held
responsible for 14% of all FTAAD.
Media degeneration represents the com-
mon pathomechanism. As FTAAD
occurs at a young age, it is considered
a more aggressive clinical entity [29].
Aneurysms aremost frequently localized
in the thoracic aorta (66%), followed by
AAA (25%) and cerebral aneurysms
(8%). Aneurysms and dissections are
equally distributed at 50%. The indi-
cations to treat aneurysms are based
on thresholds in sporadic or non-syn-
dromic aneurysms: thoracic 6.0 cm and
infrarenal 5 cm. As with LDS, a rapid
growth rate is seen in the familial form
(0.21 cm/year) compared with 0.16 cm/
year in sporadic aneurysms. Further in-
formation on familial abdominal aortic
aneurysms (fAAA) can be found in the
recommended overview articles by van
de Luijtgaarden et al. [30, 31].
EVAR and TEVAR in genetic
aortic disease (GAD)
In principle, endovascular techniques are
not intended for the treatment of the
thoracic and abdominal aorta in patients
with genetic connective tissue disease.
In relevant approval trials, the commer-
cially available endograftswere either not
investigated in the fragile milieu of the
marfanoid aorta or indeed excluded for
this indication. The long-term radial
force of the endograft, the prerequisite
of an anchor zone with sealing proper-
ties, cannot be predicted in this patient
group. Thus, the application of endovas-
cular techniques in genetic aortic dis-
ease (GAD) patients falls a priori outside
the IFU (. Fig. 1). Milewicz et al. [19]
recommend EVAR/TEVAR only for late,
chronic pseudoaneurysmsof residual na-
tive aortic segments in a graft-to-graftap-
proach. . Fig. 2presents a case studywith
this indication fromourownpatientpop-
ulation. A 2008 consensus publication,
as well as the European Society of Vascu-
lar Surgery (ESVS) guidelines due to be
published shortly, clearlyopposeprimary
endovascular treatment [20, 32]. In indi-
vidual cases, patients with a signiﬁcantly
increased risk for an open surgical pro-
cedure can be considered for an endovas-
cular approach at a recognized center for
the treatment of complex aortic diseases
[20, 32]. It is generally accepted in such
cases that the indication is given for pa-
tients in an emergency setting in whom
endovascular treatment represents a life-
saving bridging procedure until deﬁni-
tive open repair can be performed. This
means that patients can be taken out of
the life-threatening situation posed by
rupture or the threat of rupture in the
case of aortic pain or organmalperfusion
while an elective conversion is planned
in the interim.
Our own working group reported
in 2008 on early clinical experiences in
167 GAD patients, 8 of which under-
went TEVAR. Striking features at a mean
follow-up of 34 months included a high
primary endoleak rate of 38%, a reinter-
vention rate of 25% and, in particular,
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a rate of disease progression with de
novo aneurysms of again 38%. There
were no aorta-related deaths [33]. In
conclusion, TEVAR was deemed viable
as a bridging method due to the low
periprocedural mortality rate. A 2015
review conducted by Parisi et al. [34]
summarized the largest published series
in table form (. Table 2 and 3).
Endovascular treatment in patients
with EDS (type IV) primarily com-
prises coil embolization of supra-aortic
branches of the aortic arch or other
medium-sized arteries in the context
of bleeding [25]. These endovascular
occlusion techniques are particularly
suited to cases of spontaneous tearing in
the visceral artery walls, particularly the
hepatic and splenic arteries. A frequent
and classical complication of type IV
EDS is a carotid cavernous ﬁstula, which
presents as insidious, progressive prop-
tosis (exophthalmos) or in association
with headaches. Coil embolization can
be performed in selected patients if the
riskof sacriﬁcing the intracranial internal
carotid artery and subsequent stroke can
be ruled out at the planning stage using
high-resolution imaging techniques.
If there is a relevant predisposition
to false aneurysm formation and access
vessel rupture (generally the common
femoral artery), percutaneous access
needs to be considered as opposed to
open surgical cut-down, particularly
in the case of relevant sheath diame-
ters (>8 French) [35]. Open repair is
recommended in the case of access com-
plications of this kind [21]. As there are
no large series on EVAR and TEVAR in
type IV EDS, it is not possible to make
study-based recommendations at this
point; however, similar considerations
to those in Marfan’s syndrome apply.
Due to the fragility of the aortic wall,
the questionable durability of endovas-
cular treatment and the resulting higher
reintervention rate, extreme caution is
advised. Although, in the authors’ opin-
ion, there is a justiﬁcation for exceptions,
such as emergency bridging, these need
to be justiﬁed on an individual basis,
require that patients be provided with
detailed information on alternatives if
time permits and require careful doc-
umentation in the surgical report. It
is generally accepted that EVAR and
TEVAR should be avoided for type IV
EDS [20]. Due to the extremely high risk
of injury and rupture, even supposedly
simple angiography should be avoided.
A study by Cikrit et al. reported a 67%
complication rate and a 12% mortality
rate for digital subtraction angiography
(DSA) [35]. It is possible that future
low-proﬁle catheters and endografts
may be able to reduce these relevant
rates. The use of non-invasive cross-
sectional imaging with the possibility
of three-dimensional reconstruction is
increasingly reducing these risks. Should
endovascular treatment nevertheless be
necessary, direct suture of the access
vessel is recommended.
Endovascular treatment is not recom-
mended in LDS and, apart from indi-
vidual exceptions is not performed due
to the young age of these patients, the
rarity of the syndrome and the associ-
ated aortic disease. A recent bibliography
search (as of 25 July 2016 in MEDLINE/
PubMed, https://www.ncbi.nlm.nih.gov/
pubmed. nih.gov/pubmed) with “Loeys-
Dietz syndrome”and“endovascular ther-
apy” produced only two hits. In 2015,
Kalra et al. [36] reported on two patients
with LDS and contained ruptures of the
descending aorta that were successfully
managed by endovascular repair. No fol-
low-up is available. Colby [37] reported
on the technically successful treatment of
a 23-year-old female patient with a large,
dysplastic cavernous intracerebral arte-
rial aneurysm using the PipelineTM em-
bolization device (Covidien, Medtronic,
SantaRosa, CA).Complete aneurysmoc-
Gefässchirurgie · Suppl 1 · 2017 S5
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clusion was seen at 10 months following
endovascular treatment.
As inMarfan’s syndrome, conservative
drug therapy with beta-blockers is ini-
tially recommended. Due to the patho-
physiological correlations with increased
TGFbeta activity in the vessel wall, there
appears to be a clear rationale for treat-
ment with losartan. Randomized studies
on losartan treatment yielded conﬂict-
ing results. A recently published meta-
analysis by Gao et al. [38] summarized
the results from 6 randomized studies
of 1398 patients and demonstrated that
although losartan treatment signiﬁcantly
reducedaortic rootdilatation, nosurvival
beneﬁt was seen compared with the con-
trol group. Initial results from small case
series on open surgery, particularly on
the aortic root, revealed low periopera-
tive mortality rates; however, secondary
rupture at other sites was seen during
follow-up. Numerous specialist medical
societies also recommend specialized in-
terdisciplinary treatment in LDS due the
complexity of the disease [39].
» There are no large series on
EVAR and TEVAR in genetically
linked aortic disease
Thetreatment strategy inFTAADis com-
plex and non-uniform due to the vari-
able penetrance and expression of the
disease and the lack of genotype and phe-
notype correlation. No endovascular ap-
proach has been propagated or published
as yet. To date, the available consen-
sus documents have advised against such
an approach. This may be attributable
to publications from single center stud-
ies, among others, showing that patients
with fAAA exhibit a high aneurysm-re-
lated complication rate. Despite simi-
lar aneurysm morphology in 51 out of
255 fAAA patients, van de Luijtgaarden
et al. reported a two-fold higher com-
plication rate of 35.3% vs. 19.1% (haz-
ard ratio 2.1, 95% conﬁdence interval
1.2–3.7), a signiﬁcantly increased rein-
tervention rate (39.2% vs. 20.1%, p =
0.004) and greater AAA growth follow-
ing EVAR (20.8 vs.9.5%, p = 0.03). The
fact that too little attention is paid in the
diagnostic work-up to the possible pres-
ence of FTAAD undoubtedly represents
a problem in clinical routine.
Summary
The level of evidence or grade of rec-
ommendationonestablishing the indica-
tions for endovascular treatment of GAD
is limited (evidence grade II, level C).The
data on technical and clinical treatment
outcomes followingEVARandTEVAR in
genetically linked aortic disease are also
scant. Knowledgeand implementationof
the recommendations made by specialist
societies should formstrict requirements.
The diagnosis, treatment and follow-up
of patientswithGAD(e.g. MS, EDS, LDS
andTAAD)are complex, challengingand
need to be performed in an interdisci-
plinary approach [26, 40–42]. Thus, the
management of GAD should be reserved
for specialized centers with appropriate
clinical and surgical experience.
Conclusion
4 Vascular surgeons should be aware of
the four most important genetically
linked vascular and aortic diseases:
MS, EDS, LDS and FTAAD.
4 Thanks to better and earlier diagno-
sis, it has been possible to improve
life expectancy, at least in Marfan’s
syndrome, in recent years.
4 Conservative therapy, monitoring
and possibly also conventional surgi-
cal treatment should be considered
standard in the management of GAD.
4 Although endovascular repair is
primarily not indicated in the sense
of a consensus recommendation for
elective interventions, it is accepted
as a life-saving bridging procedure
and justiﬁed in individual cases.
4 Dilatation behavior and the fre-
quently related tortuosity are
causative in the high endoleak and
reintervention rates and hence in the
less favorable treatment outcomes
with EVAR and TEVAR compared with
non-syndromic aortic disease.
4 Commercially available stent grafts
have not been investigated for this
indication and, as such, are not
approved for the treatment of GAD
(use out of IFU).
4 As technological advances in stent
grafts may have a favorable impact
on therapy concepts and treatment
outcomes in the future, the signi-
ﬁcance of endovascular methods
for the treatment of GAD requires
continuous re-evaluation.
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